© 1998 by Oxford University Press
Journal of the National Cancer Institute, Vol. 90, No. 18, 1393-1399,
September 16, 1998
©Copyright 1998 Oxford University Press
REPORTS |
Benzo[a]pyrene Diol Epoxide and Bleomycin Sensitivity and Susceptibility to Cancer of Upper Aerodigestive Tract
Affiliations of authors: X. Wu, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, and The University of Texas School of Public Health, Houston; J. Gu, C. I. Amos, H. Jiang, M. R. Spitz (Department of Epidemiology), W. K. Hong (Department of Thoracic and Head and Neck Medical Oncology), J. J. Lee (Department of Biomathematics), R. J. Winn (Department of Community Oncology), The University of Texas M. D. Anderson Cancer Center; K. K.-W. Fu, Radiation Oncology Department, University of California, San Francisco; J. Cooper, Department of Radiation Oncology, New York University Medical Center, NY.
Correspondence to: Xifeng Wu, M.D., Ph.D., Box 189, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (xwu{at}notes.mdacc.tmc.edu).
Abstract
Background: Tobacco smoking is an established risk factor
for cancers of the upper aerodigestive tract, and measurement of
chromosomal aberrations, i.e., chromatid breaks, induced in lymphocytes
in vitro by bleomycin has been shown to be a predictor of risk
for these cancers. In a case–control study, we recruited case subjects
who were previously treated with surgery and/or radiotherapy for stage
I or stage II squamous cell carcinoma of the head and neck to test the
hypothesis that lymphocytic chromatid breaks induced by
benzo[a]pyrene diol epoxide (BPDE), a tobacco mutagen, may
also be associated with risk of developing cancers of the upper
aerodigestive tract. Methods: Case subjects were matched to
control subjects on the basis of age, sex, ethnicity, and smoking
status. Primary lymphocytes from 67 case subjects and 81 control
subjects were treated with 2 µM BPDE for 24 hours, and the
frequency of induced chromatid breaks was determined. All statistical
tests were two-sided. Results: Lymphocytes from case subjects
compared with lymphocytes from control subjects showed significantly
more breaks per cell induced by BPDE (mean ± standard deviation,
0.77 ± 0.38 versus 0.49 ± 0.25; P<.001). Lymphocytes
from 64.2% of case subjects were sensitive to BPDE (using a cutoff
value of 
0.60 break per cell). Subjects in the highest quartile of
chromatid breaks had an approximately 20-fold increased risk of cancer
compared with those in the lowest quartile after adjustment for age,
sex, ethnicity, and smoking status. The association between BPDE
sensitivity and cancer risk was higher in former smokers than in
current smokers and higher in younger patients than in older patients.
Subjects with sensitivity to both BPDE and bleomycin were at a
19.2-fold increased risk of cancer compared with those who were not
sensitive to either agent. Conclusions: Mutagen sensitivity
assays may aid in identifying individuals at risk of cancer, and use of
parallel assays with two mutagens may improve risk predictability. [J
Natl Cancer Inst 1998;90:1393–9]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Machella, M. B. Terry, J. Zipprich, I. Gurvich, Y. Liao, R. T. Senie, D. O. Kennedy, and R. M. Santella Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR Carcinogenesis, July 1, 2008; 29(7): 1367 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L. Crawford, T. Blomquist, D.N. Mullins, Y. Yoon, D.R. Hernandez, M. Al-Bagdhadi, J. Ruiz, J. Hammersley, and J.C. Willey CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions Carcinogenesis, December 1, 2007; 28(12): 2552 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zijno, F. Saini, and R. Crebelli Suitability of cryopreserved isolated lymphocytes for the analysis of micronuclei with the cytokinesis-block method Mutagenesis, September 1, 2007; 22(5): 311 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, J. Gu, Q. Dong, M. Huang, K.-A. Do, W. K. Hong, and M. R. Spitz Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7194 - 7201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Natarajan, N. Ganesan, P. Carter-Nolan, C. A. Tucker, P. G. Shields, and L. L. Adams-Campbell {gamma}-Radiation-Induced Chromosomal Mutagen Sensitivity Is Associated with Breast Cancer Risk in African-American Women: Caffeine Modulates the Outcome of Mutagen Sensitivity Assay. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Szekely, E. Remenar, M. Kasler, and S. Gundy Mutagen sensitivity of patients with cancer at different sites of the head and neck Mutagenesis, September 1, 2005; 20(5): 381 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lin, F. F. Kadlubar, M. R. Spitz, H. Zhao, and X. Wu A Modified Host Cell Reactivation Assay to Measure DNA Repair Capacity for Removing 4-Aminobiphenyl Adducts: A Pilot Study of Bladder Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1832 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kyoizumi, Y. Kusunoki, T. Hayashi, M. Hakoda, J. B. Cologne, and K. Nakachi Individual Variation of Somatic Gene Mutability in Relation to Cancer Susceptibility: Prospective Study on Erythrocyte Glycophorin A Gene Mutations of Atomic Bomb Survivors Cancer Res., June 15, 2005; 65(12): 5462 - 5469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O. Kennedy, M. Agrawal, J. Shen, M. B. Terry, F. F. Zhang, R. T. Senie, G. Motykiewicz, and R. M. Santella DNA Repair Capacity of Lymphoblastoid Cell Lines From Sisters Discordant for Breast Cancer J Natl Cancer Inst, January 19, 2005; 97(2): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, J. A. Roth, H. Zhao, S. Luo, Y.-L. Zheng, S. Chiang, and M. R. Spitz Cell Cycle Checkpoints, DNA Damage/Repair, and Lung Cancer Risk Cancer Res., January 1, 2005; 65(1): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Schabath, X. Wu, R. Vassilopoulou-Sellin, A. A. Vaporciyan, and M. R. Spitz Hormone Replacement Therapy and Lung Cancer Risk: A Case-Control Analysis Clin. Cancer Res., January 1, 2004; 10(1): 113 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Mohrenweiser Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm Toxicol Pathol, January 1, 2004; 32(1_suppl): 136 - 145. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Spitz, Q. Wei, Q. Dong, C. I. Amos, and X. Wu Genetic Susceptibility to Lung Cancer: The Role of DNA Damage and Repair Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 689 - 698. [Full Text] [PDF]
|
|
|
|
|
|
G. Szekely, E. Remenar, M. Kasler, and S. Gundy Does the bleomycin sensitivity assay express cancer phenotype? Mutagenesis, January 1, 2003; 18(1): 59 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, S. M. Lippman, J. J. Lee, Y. Zhu, Q. V. Wei, M. Thomas, W. K. Hong, and M. R. Spitz Chromosome Instability in Lymphocytes: A Potential Indicator of Predisposition to Oral Premalignant Lesions Cancer Res., May 1, 2002; 62(10): 2813 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Xiong, M. L. Bondy, D. Li, H. Shen, L.-E Wang, S. E. Singletary, M. R. Spitz, and Q. Wei Sensitivity to Benzo(a)pyrene Diol-Epoxide Associated with Risk of Breast Cancer in Young Women and Modulation by Glutathione S-Transferase Polymorphisms: A Case-Control Study Cancer Res., December 1, 2001; 61(23): 8465 - 8469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Li, P. F. Firozi, L.-E Wang, C. H. Bosken, M. R. Spitz, W. K. Hong, and Q. Wei Sensitivity to DNA Damage Induced by Benzo(a)pyrene Diol Epoxide and Risk of Lung Cancer: A Case-Control Analysis Cancer Res., February 1, 2001; 61(4): 1445 - 1450. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Hadi, M. A. Coleman, K. Fidelis, H. W. Mohrenweiser, and D. M. Wilson III Functional characterization of Ape1 variants identified in the human population Nucleic Acids Res., October 15, 2000; 28(20): 3871 - 3879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Berwick and P. Vineis Markers of DNA Repair and Susceptibility to Cancer in Humans: an Epidemiologic Review J Natl Cancer Inst, June 7, 2000; 92(11): 874 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, H. Yu, C. I. Amos, W. K. Hong, and M. R. Spitz Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk J Natl Cancer Inst, May 3, 2000; 92(9): 737 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Caporaso, N. Rothman, and S. Wacholder Case-Control Studies of Common Alleles and Environmental Factors J Natl Cancer Inst Monographs, December 1, 1999; 1999(26): 25 - 30. [Abstract] [Full Text]
|
|
|
|
|
|
X. Wu, M. R. Spitz, C. I. Amos, and T. C. Hsu RESPONSE: Re: Benzo[a]pyrene Diol Epoxide and Bleomycin Sensitivity and Susceptibility to Cancer of Upper Aerodigestive Tract J Natl Cancer Inst, August 4, 1999; 91(15): 1335 - 1336. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nersesyan Re: Benzo[a]pyrene Diol Epoxide and Bleomycin Sensitivity and Susceptibility to Cancer of Upper Aerodigestive Tract J Natl Cancer Inst, August 4, 1999; 91(15): 1334b - 1335b. [Full Text] [PDF]
|
|